Product Details
Product Specifications
Assay TypeSandwich-ELISAAnalyteEGFFormat96T (8×12 strips)ReactivityHumanRegulatory StatusRUOSensitivity<1.25 pg/mLStandard Curve Range1.25 pg/mL-40 pg/mLAssay Time3 h 20 minSuitable Sample TypeFor the detection and quantitative determination of EGF in cell culture supernates, serum, and plasma.Sample volume100 μLProduct Overview
resDetect™ EGF ELISA kit (Residue Testing)is based on the ELISA sandwich method and is used to detect and quantitatively determine Human EGF residues in cell culture supernatants. The kit GMP Human EGF Protein to ensure accurate assay results and is designed to provide a reliable solution for cell therapy product quality assessment during drug development and CMC quality control stages. It can also be used as a universal detection tool for the quantitative determination of Human EGF.
Application
The kit is developed for the detection and quantitative determination of EGF in cell culture supernates, serum, and plasma.
It is for research use only.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
Materials Provided
IDComponentsSizeRES133-C01Pre-coated Anti-EGF Antibody Microplate1 plate (8×12 strips)RES133-C02Human EGF Standard20 μgRES133-C03Biotin-Anti-EGF Antibody20 μgRES133-C04Streptavidin-HRP50 μLRES133-C0510×Washing Buffer50 mLRES133-C062×Dilution Buffer50 mLRES133-C07Substrate Solution12 mLRES133-C08Stop Solution7 mLACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.

For each experiment, a standard curve should be generated for each microplate. The absolute OD values may vary depending on the laboratory, operator, or equipment. The example data provided below are for reference only.
Customer Reviews Writing Reviews

Recent Advances
- English Name:
Epidermal growth factor
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
4 Details
- Highest Development Stage:
Phase 2 Clinical



